Product Description
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Ramucirumab making it ideal for research use. This Ramucirumab biosimilar reacts with human VEGFR-2 (vascular endothelial growth factor receptor 2) also known as CD309, KDR, and Flk-1. VEGFR-2 is a member of the tyrosine protein kinase family. Upon binding to its ligand VEGF, VEGFR-2 pays key roles in vascular development and permeability. VEGFR-2 is expressed on endothelial cells at high levels in adult heart, lung, kidney, brain, and skeletal muscle as well as other tissues at lower levels. Ramucirumab binds to the extracellular domain of VEGFR-2 and blocks the binding of VEGFR ligands VEGF-A, VEGF-C and VEGF-D leading to inhibition of VEGF-mediated tumor angiogenesis.
* VAT and shipping costs not included. Errors and price changes excepted
